義翹神州(301047.SZ):網上定價發行的中籤率為0.0107201435%
格隆匯8月3日丨義翹神州(301047.SZ)披露首次公開發行股票並在創業板上市網上定價發行申購情況及中籤率公吿,保薦機構(主承銷商)根據深交所提供的數據,對本次網上發行的申購情況進行了統計,結果如下:
本次網上定價發行有效申購户數為15,034,235户,有效申購股數為158,579,966,500股,配號總數為317,159,933個,起始號碼為000000000001,截止號碼為000317159933。本次網上定價發行的中籤率為0.0107201435%,網上投資者有效申購倍數為9,328.23332倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.